Trial Profile

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XmAb 819 (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma
Focus Adverse reactions; First in man
Sponsors Xencor

08 Jan 2026 According to a Xencor media release, the compay to initiate tumor expansion cohorts in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and papillary renal cell carcinoma (pRCC) during 2026.
08 Jan 2026 According to a Xencor media release, the company to present new clinical data to support a recommended Phase 3 dose in 2H26.
26 Oct 2025 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com